Because previous studies revealed that high levels of antibody to the group A streptococcal carbohydrate (A-antibody) persist in the serum of patients with chronic rheumatic valvular disease, the effect of valvular surgery on the level of this antibody was examined in the present study. Streptococcal antibody titers (ASO, anti-DNAse B, and A-antibody) were determined on 73 patients admitted for cardiac surgery: 36 with chronic rheumatic valvular disease and 37 with nonrheumatic cardiac or coronary disease. While the ASO and anti-DNAse B presurgical titers were similar in rheumatic and nonrheumatic individuals, the levels of A-antibody were significantly higher in rheumatic patients. The effect of blood perfusion during cardiac surgery was reflected by reversion of antibody titers towards the mean value for a normal population. A trend toward a rise in all antibodies was seen in all patients two to seven weeks after surgery. However, after an interval of eight weeks or more following surgery, a significant decline in the A-antibody occurred in rheumatic patients who had undergone excision and replacement of the affected valve, but not in those who had experienced a simple commissurotomy. These findings provide additional evidence to support a relationship between valvular disease and A-antibody level in rheumatic patients.
periods in patients with chronic rheumatic valvular heart disease.12 In contrast, observations on patients with congenital valvular disease have shown serum Aantibody levels to be in the normal range.'3' 14 These findings lend support to the possibility of a pathogenetic relationship between the presence of Aantibody and chronic rheumatic valvular damage.
Further evidence for such a relationship was sought in the present study by examining the effect of valvuloplasty and valvectomy on the level of the serum A-antibody in rheumatic patients undergoing valvular surgery.
Materials and Methods Seventy-three patients admitted for cardiac surgery either at the Shands Teaching Hospital of the University of Florida Medical Center or at the Bellevue Hospital of the New York University Medical School were included in this study. These consisted of patients with rheumatic valvular disease, congenital heart disease, and coronary occlusive disease (table 1) . The medical records of each patient were reviewed and their assignment to a rheumatic etiology was predicated on a history compatible with a prior episode of acute rheumatic fever, with manifestations fulfilling the modified Jones Criteria,15 and the presence at surgery of findings consistent with rheumatic valvular disease.
Of the 36 patients with rheumatic valvular disease, 19 had undergone excision and replacement of a single valve with a prosthetic device, the mitral valve was replaced in 13, and (19 patients) or for coronary occlusive disease (12 patients), served as controls.
The ages of the patients with rheumatic heart disease at the time of surgery ranged from 12 to 64 years with a median age of 31 years. The group of patients undergoing valvuloplasty was younger than those undergoing valvular replacement, the median ages being 15 and 47 years, respectively. The age range of the patients with nonrheumatic heart disease was 4 to 69 years, with a median age of 33 years. The sex distribution of the patients with rheumatic heart disease was even -20 males and 22 females. Eighteen of the nonrheumatic patients were males and 13 were females; all but one of the 12 patients undergoing surgery for coronary occlusive disease were males.
Blood was obtained by venipuncture prior to surgery. Thereafter, blood samples were drawn on the first operative day and subsequently at weekly or biweekly intervals for a period of two to three months. Sporadic bleedings were obtained on some of these patients several months after surCirculation, Volume 50, July 1974 gery. The sera were separated under aseptic conditions and stored at -10C until the time of assay. The sera from each patient were assayed simultaneously for each antibody in order to evaluate more accurately variations in the titers.
Assays for anti-streptolysin 0 (ASO) and antidesoxyribonuclease B (anti-DNAse B) were performed using microtechniques previously described.", 17 The serum dilution scheme for the ASO and anti-DNAse B titers was based on a logarithmic scale, with 0.1 log separating each of the consecutive tube dilutions. Because assessment of individual or group differences is based on differences in logs of titers or geometric means of titers respectively, the values obtained for the ASO and anti-DNAse B were reported as logs of antibody titers. The antibody to the streptococcal group A carbohydrate (A-antibody) was determined by the radioimmune precipitin technique.12 The antibody levels in this test represent the fraction of the total amount of radioactive antigen precipitated by a constant amount (0.2 ml) of serum. The antibody scale for this test spans from 0.00 to 1.00 "units," with the antibody levels ofvarious sera differing by multiples of 0.01 units. All three antibody tests were assayed on the sera of each patient except in a few instances where the quantity of serum available was insufficient to determine either the ASO or anti-DNAse B titers.
Results

Distribution of Streptococcal Antibodies in Patients
Prior to Surgery
The distribution of the streptococcal antibody titers obtained prior to surgery for the rheumatic patients and nonrheumatic controls is outlined in figure 1 . The ASO titers of the control and rheumatic groups of patients are similar. The mean log titer for the antiDNAse B titers is somewhat higher for the rheumatic group, but the difference from that of the control group is not significant (P > 0.05). The distribution of the A-antibody levels reveals the same pattern observed for similar populations in previous studies. 12 To assess the significance of these changes, the 95% confidence limit (± 2 standard errors of the mean multiplied by the correction factor for small numbers at the 95% confidence limit"8) was calculated for each mean value. Changes exceeding the 95% confidence limit were considered significant. As shown in figure 3 , a significant rise in ASO titers occurred at 2-4 weeks in the nonrheumatic patients. In this group of patients, the ASO titers showed a tendency to remain elevated throughout the follow-up period, in contrast to the rheumatic population where the general tendency for the ASO was to decline. Similarly, the anti-DNAse B showed a significant rise at 2-4 weeks, as well as at the 5-7 week postoperative period for the nonrheumatic patients ( fig. 4) . In both rheumatic categories, an initial decline in the antiDNAse B was noted during the first week followed by The changes in the A-antibody levels for the three patient categories are shown in figure 5 . The nonrheumatic controls and rheumatic patients undergoing commissurotomy showed a tendency toward a rise in the A-antibody levels throughout the 2-month postsurgical period. In contrast, rheumatic patients undergoing valvectomy showed a trend toward a postoperative decline in the antibody level which was significant eight weeks and later after surgery. 6 , were found to be significantly different (P < 0.001). In addition, it can be seen that the majority of the patients undergoing commissurotomy showed a rise in the A-antibody level, while almost all patients undergoing valvectomy experienced a decline in their Aantibody level. An analysis of the frequency with which the patients in each group showed a rise or a decline in titer, i.e., values greater or lower than the "O" baseline, yielded a x2 of 7.2 (P < 0.01). Distribution of individual differences between the presurgical Aantibody levels and levels obtained eight weeks or later after surgery for rheumatic patients undergoing commissurotomy and those uindergoing valve resection.
Discussion
The description by Goldstein and his coworkers-1' of an immunological relationship between the group A streptococcal carbohydrate and the cardiac valvular glycoprotein has raised speculation regarding the role of antibody to this streptococcal antigen in the pathogenesis of rheumatic valvular heart disease. These investigators showed that group A streptococcal antiserum reacted with glycopeptides extracted from bovine or human heart valves. Recent work by KaspGrochowska et al. '9' 20 Previous studies in our laboratory have shown persistence of antibody to the streptococcal group A carbohydrate in patients with rheumatic valvular disease.12 Because these studies suggested a relationship between this antibody and rheumatic valvular disease, the present study was carried out to determine the effect of valvular surgery in rheumatic patients on the A-antibody level. The data obtained initially showed variable changes in the antibody to the various streptococcal antigens with no particular difference in the changes observed between the rheumatic and nonrheumatic patients undergoing open heart surgery. Closer examination revealed some significant differences, however. These differences, some of which were common to all patients and otherspeculiar to one group, pertained to apparent changes in antibody levels at various intervals following cardiac surgery, as well as to changes within the rheumatic group which related to whether the valve was resected or left in situ.
The first change observed immediately postoperatively occurred in all patient categories studied. A decline or rise which was related to the presurgical antibody titer occurred in the various antibodies. As shown, this change represented the effect of exchange transfusion concurrent with the use of the pump oxygenator and replacement of the patient's blood with blood from normal donors. While this change was most prominent during the first 24 hours after surgery for all three antibodies tested, the trend persisted partially through the first postoperative week for the ASO and anti-DNAse B titers.
The second observation, which was less uniform, was the change in antibody titers during the following 
